• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 15-12B filed by Itamar Medical Ltd.

    12/27/21 6:02:01 AM ET
    $ITMR
    Medical/Dental Instruments
    Health Care
    Get the next $ITMR alert in real time by email
    15-12B 1 tm2136338d1_15-12b.htm 15-12B

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 15

     

    CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

     

    Commission File Number 001-38775

     

    Itamar Medical Ltd.

     

    (Exact name of registrant as specified in its charter)

     

    9 Halamish Street, Caesarea 30888900, Israel

     

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Ordinary Shares, par value NIS 0.01 per share

    American Depository Shares, each representing 30 Ordinary Shares, par value NIS 0.01 per share 

     

    (Title of each class of securities covered by this Form)

     

     

     

    (Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

     

    Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

     

    Rule 12g-4(a)(1)  x
    Rule 12g-4(a)(2)  ¨
    Rule 12h-3(b)(1)(i)  x
    Rule 12h-3(b)(1)(ii)  ¨
    Rule 15d-6  ¨
    Rule 15d-22(b)  ¨

     

    Approximate number of holders of record as of the certification or notice date: _______________________________

     

    Pursuant to the requirements of the Securities Exchange Act of 1934 (Name of registrant as specified in charter) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

     

    Date: December 16, 2021                   By: /s/ Shy Basson, Chief Financial Officer                              

      

    Instruction: This form is required by Rules 12g-4, 12h-3, 15d-6 and 15d-22 of the General Rules and Regulations under the Securities Exchange Act of 1934. The registrant shall file with the Commission three copies of Form 15, one of which shall be manually signed. It may be signed by an officer of the registrant, by counsel or by any other duly authorized person. The name and title of the person signing the form shall be typed or printed under the signature.

     

     

     

     

      

    SEC 2069 (08-11)

    Persons who respond to the collection of information contained in this form are

    not required to respond unless the form displays a currently valid OMB control

    number.

     

     

     

    Get the next $ITMR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ITMR

    DatePrice TargetRatingAnalyst
    9/20/2021$30.00 → $31.00Outperform → Market Perform
    SVB Leerink
    9/15/2021$33.85Buy → Neutral
    Ladenburg Thalmann
    9/14/2021$36.00 → $31.00Buy → Neutral
    HC Wainwright & Co.
    9/14/2021$30.00 → $31.00Outperform → Market Perform
    Cowen & Co.
    More analyst ratings

    $ITMR
    SEC Filings

    See more
    • SEC Form 15-12B filed by Itamar Medical Ltd.

      15-12B - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 6:02:01 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Itamar Medical Ltd.

      EFFECT - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 12:15:19 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Itamar Medical Ltd.

      EFFECT - Itamar Medical Ltd. (0001613170) (Filer)

      12/27/21 12:15:09 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Financials

    Live finance-specific insights

    See more
    • Itamar Medical Reports Third Quarter 2021 Financial Results

      - Revenues Increased 23% Year-over-Year to $13.6 Million - - U.S. WatchPAT™ Revenues Increased 27% Year-over-Year to $11.3 Million - CAESAREA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the third quarter of 2021. "Third quarter results represent the strong traction our WatchPAT™ platform technology has gained entering the second half of 2021. Growth in the U.S. continues to outpace our overall growth on top of expanding adoption in the markets we serve thr

      11/18/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Reports Second Quarter 2021 Financial Results

      - Revenues Increased 41% Year-over-Year to $12.6 Million - - U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million - - Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the second quarter of 2021. "Our second quarter results demonstrated further growth as our WatchPAT™ technol

      8/10/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical to Report Second Quarter Financial Results and Host Conference Call on Tuesday, August 10, 2021

      CAESAREA, Israel, July 28, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, announced today that it will report its financial results for the second quarter 2021 before the U.S. market opens on Tuesday, August 10, 2021. The Company will host a conference call that day at 8:00 a.m. Eastern Time, 3:00 p.m. Israel Time to review financial results and provide a corporate update. The call will be hosted by Gilad Glick, President and CEO, and Shy Basson, CFO. To listen live via webcast, please visit https://edge.media-server.com/mm

      7/28/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Itamar Medical Ltd. (Amendment)

      SC 13G/A - Itamar Medical Ltd. (0001613170) (Subject)

      10/4/21 6:02:57 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Itamar Medical Ltd. (Amendment)

      SC 13G/A - Itamar Medical Ltd. (0001613170) (Subject)

      6/17/21 11:07:03 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed

      SC 13G - Itamar Medical Ltd. (0001613170) (Subject)

      2/16/21 6:35:46 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Itamar Medical downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Itamar Medical from Outperform to Market Perform and set a new price target of $31.00 from $30.00 previously

      9/20/21 6:33:53 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical downgraded by Ladenburg Thalmann with a new price target

      Ladenburg Thalmann downgraded Itamar Medical from Buy to Neutral and set a new price target of $33.85

      9/15/21 7:36:23 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical downgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. downgraded Itamar Medical from Buy to Neutral and set a new price target of $31.00 from $36.00 previously

      9/14/21 6:31:39 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Leadership Updates

    Live Leadership Updates

    See more
    • Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors

      CAESAREA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors. Ms. Ortigas-Wedekind brings more than 30 years of medical technology and digital health experience including leadership roles in commercial and strategic marketing. She is currently the Chief Commercial Strategy Officer for Fogarty Innovation, a nonprofit organization in the medical technology space. In this role she is responsible for delivering commercial strategy gu

      8/12/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Appoints Brad Fluegel to its Board of Directors

      CAESAREA, Israel, May 24, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Brad Fluegel to its Board of Directors. Mr. Fluegel's vast experience includes wide ranging leadership roles and 25+ years in the healthcare sector, primarily in strategy and business development. Most recently, Mr. Fluegel was Senior Vice President, Chief Healthcare Commercial Market Development Officer for Walgreens Co. In this role he was responsible for driving all commercial healthcare activities, including sales

      5/24/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care

    $ITMR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Itamar Medical Reports Third Quarter 2021 Financial Results

      - Revenues Increased 23% Year-over-Year to $13.6 Million - - U.S. WatchPAT™ Revenues Increased 27% Year-over-Year to $11.3 Million - CAESAREA, Israel, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the third quarter of 2021. "Third quarter results represent the strong traction our WatchPAT™ platform technology has gained entering the second half of 2021. Growth in the U.S. continues to outpace our overall growth on top of expanding adoption in the markets we serve thr

      11/18/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors

      CAESAREA, Israel, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (NASDAQ and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today announced the appointment of Marga Ortigas-Wedekind to its Board of Directors. Ms. Ortigas-Wedekind brings more than 30 years of medical technology and digital health experience including leadership roles in commercial and strategic marketing. She is currently the Chief Commercial Strategy Officer for Fogarty Innovation, a nonprofit organization in the medical technology space. In this role she is responsible for delivering commercial strategy gu

      8/12/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care
    • Itamar Medical Reports Second Quarter 2021 Financial Results

      - Revenues Increased 41% Year-over-Year to $12.6 Million - - U.S. WatchPATTM Revenues Increased 53% Year-over-Year to $10.1 Million - - Raised Full Year 2021 Revenue Guidance to a Range of $53 Million to $54 Million - - Company to Host Conference Call Today at 8:00 am ET, 3:00 pm IT - CAESAREA, Israel, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq and TASE: ITMR), a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, today reported unaudited financial results for the second quarter of 2021. "Our second quarter results demonstrated further growth as our WatchPAT™ technol

      8/10/21 6:00:00 AM ET
      $ITMR
      Medical/Dental Instruments
      Health Care